Chief Technical Officer Ted Lamson to Receive Prestigious Industry
Award for Innovation
WAYNE, Pa.--(BUSINESS WIRE)--Sep. 17, 2018--
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX)
focused on addressing unmet needs in the field of urology, today
announced that new clinical data from numerous studies of the UroLift®
System for patients with benign prostatic hyperplasia (BPH) will
be presented at the 36th World Congress of Endourology (WCE) 2018 Annual
Conference taking place September 20-23 in Paris.
The company also announced that co-founder and chief technical officer,
Ted Lamson, Ph.D., co-inventor of the UroLift System, will be receiving
the 2018 Industry Award for Innovations in Endourological
Instrumentation from the Endourological Society. The award will be
presented during the Plenary Session by Eduardo Mazzucchi, M.D.,
Chairman of the Endourological Society, on September 23 at 11:20 a.m. in
Amphitheatre Bleu.
“I am honored to be recognized by the Endourological Society for the
2018 Industry Award,” said Dr. Lamson. “It is incredibly gratifying to
have played a role in helping tens of thousands of patients achieve an
improved quality of life free from the burdensome symptoms of BPH. While
I am delighted to accept this honor, I do so on behalf of the hundreds
of employees, physicians and practices that have played key roles in
bringing the UroLift System treatment into the BPH standard of care.”
Multiple presentations focus on the real-world clinical setting,
evaluating the clinical and health economic performance of the UroLiftSystem treatment for patients with BPH. Additionally, a moderated
BPH Session and Semi-Live Surgery will be presented on Sunday, September
23 in Amphitheatre Bleu.
WCE presentations on the UroLift System include (all times local):
Friday, September 21
-
“UroLift in the Management of Acute Urinary Retention” will be
presented by Ashok Kar, M.D., Affiliated Urologists of Orange County,
at 10:00 a.m.
-
“Predictors of Response to the Prostatic Urethral Lift (PUL)
Treatment” will be presented by Claus Roehrborn, M.D., University of
Texas Southwestern Medical Center, at 2:00 p.m.
-
“Real World Experience with the Prostatic Urethral Lift” will be
presented by Mark Rochester, M.D., Norwich University Hospital, at
2:00 p.m.
Saturday, September 22
-
“Early Experience with UroLift for Benign Prostatic Hyperplasia in an
Australian Public Hospital” will be presented by Justin Chee, M.D.,
Western Health, Melbourne, at 8:30 a.m.
-
“First Time, Real-World Experience with the UroLift Device Closely
Mimics the LIFT Trial Data: A Single Surgeon Experience” will be
presented by Campbell Bryson, M.D., Yale New Haven Hospital, at 8:30
a.m.
-
“Does Size Matter? Performance of Prostatic Urethral Lift in Men with
Prostate Volumes < 30 grams and > 80 grams” to be presented by Greg
McMahon, M.D., Rowan University of Osteopathic Medicine, Stratford, at
8:30 a.m.
Sunday, September 23
-
“Transforming BPH Surgical Care to an Ambulatory Setting - What are
the Gains and Losses?” will be presented by Oliver Kayes, M.D., Leeds
Teaching Hospitals NHS Trust, at 10 a.m.
-
“Cost Reductions with Prostatic Urethral Lift for BPH” will be
presented by Dr. Kayes at 10 a.m.
-
“Plenary BPH Session - Prostatic Urethral Lift Procedure” will be
presented by Christopher Netsch, M.D., Asklepios Klinik Barmbek,
Hamburg, and moderated by Gopal Badlani, M.D., Wake Forest Baptist
Medical Center, at 11:35 a.m. in Amphitheatre Bleu.
-
“Semi-Live Surgery: Prostatic Urethral Lift” with surgeon Gregoire
Robert, M.D., Ph.D., Bordeaux University Hospital, and moderated by
Dr. Badlani and Alexey Martov, M.D., Ph.D., Federal Medical-Biological
Agency of Russian Federation State Institute of Continuous Medical
Education, at 1:50 p.m. in Amphitheatre Bleu.
About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive
technology for treating lower urinary tract symptoms due to benign
prostatic hyperplasia (BPH). The UroLift permanent implants, delivered
during a minimally invasive transurethral outpatient procedure, relieve
prostate obstruction and open the urethra directly without cutting,
heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
enlarged prostate receiving UroLift implants reported rapid and durable
symptomatic and urinary flow rate improvement without compromising
sexual function. Patients also experienced a significant improvement in
quality of life. Nearly 70,000 men have been treated with the UroLift
System. Most common adverse events reported include hematuria, dysuria,
micturition urgency, pelvic pain, and urge incontinence. Most symptoms
were mild to moderate in severity and resolved within two to four weeks
after the procedure. The UroLift System Prostatic Urethral Lift
procedure is recommended for the treatment of BPH in both the American
Urological Association and European Association of Urology clinical
guidelines. The UroLift System is available in the U.S., Europe,
Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract
Interventional Urology Business Unit is dedicated to developing
innovative, minimally invasive and clinically effective devices that
address unmet needs in the field of urology. Our initial focus is on
improving the standard of care for patients with BPH using the UroLift
System, a minimally invasive permanent implant system that treats
symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®,
Rusch®, UroLift® and Weck® – trusted brands united by a common sense of
purpose.
MAC00843-01 Rev A
View source version on businesswire.com: https://www.businesswire.com/news/home/20180917005085/en/
Source: Teleflex Incorporated
For Teleflex Incorporated:
Jake Elguicze, 610-948-2836
Treasurer
and Vice President, Investor Relations
or
Media:
Nicole
Osmer, 650-454-0505
nicole@healthandcommerce.com